Chongqing Taihao Pharmaceutical Co., Ltd.

Chongqing Taihao Pharmaceutical Co., Ltd. was established in 2004 and is a high-tech, internationalized API manufacturing enterprise. It is mainly engaged in the research and development, production, and sales of plant extract APIs, semi-synthetic APIs, chemical APIs, and pharmaceutical intermediates.

Taihao Pharmaceutical is a high-tech enterprise in Chongqing, with API production workshops that comply with current international/domestic Good Manufacturing Practices, excellent professional and technical personnel in research and development, registration, production, and quality management; and advanced testing instruments and equipment imported from Europe, America, and Japan.

Taihao Pharmaceutical fully implements and strictly follows cGMP guidelines (ICH Q7A), and has gradually introduced ICH Q8, Q9, and Q10, establishing a sound quality assurance system. Taihao Pharmaceutical currently has multiple API products that have passed on-site GMP inspections by pharmaceutical regulatory authorities such as the U.S. Food and Drug Administration (US FDA), the European Directorate for the Quality of Medicines (EDQM), the Pharmaceuticals and Medical Devices Agency of Japan (PMDA), and the China Food and Drug Administration (CFDA).
Taihao Pharmaceutical is committed to market development and has established close cooperative relationships with a number of international multinational pharmaceutical companies. Its products are mainly sold to markets such as the United States, Europe, Australia, Japan, South Korea, China, and Russia.

Taihao Pharmaceutical adheres to the purpose of "producing high-quality medicines and serving human health" and is committed to building a first-class anti-tumor API production base in China.